For personal use only

ASX RELEASE

13 February 2017

MMJ ENTERS AGREEMENT TO STRENGTHEN AUSTRALIAN DISTRIBUTION NETWORK

- **Binding LOI entered with HL Pharma Pty Ltd. for the importation and distribution of MMJ's medicinal cannabis products**
- **MMJ to work with HL Pharma to secure all necessary import licenses and permits**
- **Partnership will play a key role in MMJ's entry into Australian medicinal cannabis market and establishment of a secure supply chain**

MMJ PhytoTech Limited (ASX: MMJ) ("MMJ" or **"the Company")** is pleased to advise that it has entered into a binding Letter of Intent ("LOI") with HL Pharma Pty Ltd. ("HL Pharma") for the importation and distribution of the Company's medicinal cannabis products in Australia.

Under the agreement, HL Pharma will assist with establishing an Australian dispensary framework that enables the distribution of MMJ's medicinal cannabis products to approved customers.

Following recent changes to Australian Commonwealth legislation, legalising medicinal cannabis as a controlled prescription drug, MMJ will initially look to supply the Australian market with its sophisticated oral delivery products developed by its Switzerland-based subsidiary Satipharm AG ("Satipharm").

HL Pharma is a Melbourne-based specialist pharmaceutical wholesaler and distributor. The Company has more than 20 years of experience, supplying pharmaceuticals to hospitals, pharmacies, doctors, veterinarians and pharmaceutical wholesalers worldwide. HL Pharma is registered with The Victorian Department of Health and works under the code of Good Distribution Practice ("GDP") to supply pharmaceuticals.

MMJ PhytoTech's Managing Director, Andreas Gedeon, commented:

"We are very pleased to be partnering with HL Pharma to further establish our Australian supply chain, as we view the Australian medicinal cannabis market as an important part of the business.

With legislation continuing to evolve, it is advantageuos for MMJ to establish relationships with highly experienced local partners such as HL Pharma, to ensure a seamless entry into this market.

We look forward to providing our shareholders with further corporate and operational updates in the near-term."

-ENDS-

Suite 5 CPC, 145 Stirling Highway, Nedlands WA 6009 | **PO Box 3144,** Nedlands WA 6009
Phone +61(0) 8 9389 3150 | **Fax** +61(0) 8 9389 3199 | **Email** info@mmjphytotech.com.au
Web www.mmjphytotech.com.au | **ABN** 91 601 236 417

For personal use only

ASX RELEASE

For media and investor inquiries please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067

Follow us on Twitter @MMJPhytoTechLtd

http://www.mmjphytotech.com.au

About MMJ PhytoTech Limited

MMJ PhytoTech Limited (ASX. MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through three business units, strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

United Greeneries Holding Ltd. has established world-class growing facilities in Canada, including the fully licensed Duncan Facility. MMJ is the first Australian-based company to receive a Canadian medicinal cannabis cultivation licence, and one of only a few companies globally with the capacity to commercially cultivate medicinal grade cannabis in a federally regulated environment.

The Company's European, cannabis-based, pharmaceutical, nutraceutical and cosmetics division operates under its 100% owned subsidiary, **Satipharm AG**. MMJ began production of its Gelpell ® Microgel Capsules in May 2015, and is committed to boosting the sales of its flagship product throughout regulated markets globally.

MMJ's Israel-based subsidiary, **PhytoTech Therapeutics Ltd**, is responsible for the Company's R&D activities, with a key focus on the development and commercialisation of new and existing delivery systems and devices that have the potential to deliver safe, effective and measured doses of medicinal cannabis to patients.